Cell exposure
Laboratory experiments measured markers after controlled in-vitro exposure.
Protocol / Research Dosing Guide
Cartalax Dosage Guide: Community Schedule, Reconstitution and Safety
An evidence-organized Cartalax reference separating AED cell-culture research from unvalidated community dosing and product claims.
Last reviewed September 15, 202618 minute readResearch information only
Level 2 — Preclinical evidenceNo verified human trialsNot FDA approved
Cartalax Quick Start
Cartalax is the tripeptide Ala-Glu-Asp, abbreviated AED. Research has examined cell-culture markers related to cartilage and aging, but no controlled human trial, human pharmacokinetic study, or validated clinical regimen was identified.
Why researchers care
Cartilage, connective-tissue, and cell-aging research
Class
Synthetic AED tripeptide bioregulator
Route reported
Subcutaneous use is community reported
Cycle length
Up to 12 weeks reported; not validated
Regulatory status
Not FDA approved
Loading supplier information
Cartalax Dosing Protocol and Schedule
The supplied source presents a 2-to-5 mg daily, 12-week community titration and also mentions a separate 10 mg for 20 days pattern. Neither schedule comes from a controlled human dose-finding study.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Weeks 1–2 | 2 mg daily | Community reported |
| Weeks 3–4 | 3 mg daily | Community reported |
| Weeks 5–8 | 4 mg daily | Community reported |
| Weeks 9–12 | 5 mg daily | Community reported |
The 200 ng/mL concentration used in cell experiments cannot be converted into a human dose. No human amount, cycle, or rest period is established.
Cartalax Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
Cartalax Reconstitution Calculator
Vial-format concentration math
Concentration
6.667 mg/mL
Draw volume
0.3 mL
U-100 units
30
Mathematical draws
10
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Cartalax: Morning or Night?
Morning or evening?
Not established; source timing is community convention.
Once daily?
Daily use is community reported and not trial validated.
With food?
Not applicable to the reported vial route and not established.
Missed amount?
No validated replacement or doubling instructions exist.
Cartalax Route Comparison
| Route | Research context | Evidence limit |
|---|---|---|
| Cell culture | Human stem cells and fibroblasts | In vitro, not clinical exposure |
| Isolated rat chondrocytes | Preclinical tissue research | Not whole-animal dosing |
| Subcutaneous | Community reported | No human route study |
| Oral or lingual | Commercial products reported | Formulations and exposure not established |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Cartalax Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No human PK study |
| Animal half-life | Not established | No in-vivo PK study located |
| Bioavailability | Not established | No route-specific exposure data |
| Frequency | Daily is community reported | Not experimentally validated |
Cartalax Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 2 mg | Daily, weeks 1–2 | Community report | No |
| Subcutaneous | 3 mg | Daily, weeks 3–4 | Community report | No |
| Subcutaneous | 4 mg | Daily, weeks 5–8 | Community report | No |
| Subcutaneous | 5 mg | Daily, weeks 9–12 | Community report | No |
| Cell culture | 200 ng/mL | Experimental concentration | In vitro research | Not convertible |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Cartalax Reconstitution Guide
Concentration: 6.667 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 2 mg | 0.3 mL | 30 units |
| 4 mg | 0.6 mL | 60 units |
| 6 mg | 0.9 mL | 90 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Cartalax Works
AED sequence
Cartalax is the short peptide Ala-Glu-Asp.
Cartalax Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved
- No controlled human Cartalax trial was identified.
- Human mesenchymal stem-cell studies used replicative-aging models in vitro.
- Rat chondrocyte work used isolated cell culture rather than whole-animal administration.
- Human fibroblast studies examined gene-expression markers in vitro.
- Direct literature is limited and concentrated within a small research group.
Who Should Avoid Cartalax?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Joint disease needing diagnosis
No demonstrated clinical efficacy
Known ingredient sensitivity
Potential allergic risk
Concurrent medicines
No interaction studies
Long-term or repeated use
No safety data
Cartalax Side Effects, Risks and Safety
Injection-site irritationAnecdotal
Important limitation: No controlled incidence data.
Systemic adverse effectsUnknown
Important limitation: No human safety dataset.
Immune reactionUnknown
Important limitation: No characterized immunogenicity data.
Drug interactionsUnknown
Important limitation: No interaction studies.
Reproductive safetyUnknown
Important limitation: No pregnancy or fertility data.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
Cartalax Timeline and Monitoring
12 weeks
Community titration period, not a clinical study duration.
20 days
A separate community schedule; not validated.
Repeat cycle
Not established; no restart criteria or cumulative-exposure limits exist.
Cartalax Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Cartilage differentiation markers | Laboratory evidence | Human stem-cell models | Does not establish joint outcomes |
| Chondrocyte activity | Preclinical | Isolated rat-cell experiments | Not whole-animal efficacy |
| Skin-fibroblast aging markers | Laboratory evidence | In-vitro gene-expression studies | Clinical meaning unknown |
| Joint pain or mobility | Not established | Community claim | No controlled human trial |
Cartalax Storage and Handling
Unreconstituted vial
No Cartalax-specific stability study was identified.
Prepared vial
Community refrigeration guidance is not validated stability evidence.
Oral or lingual products
Formulations may contain other ingredients and are not interchangeable.
Appearance
Visual inspection cannot establish identity, purity, or sterility.
Cartalax Troubleshooting
The solution looks abnormal
Stop and seek qualified product guidance; appearance cannot confirm sterility.
The units differ from another chart
Recheck vial mg, liquid mL, target mg, and U-100 conversion.
A cell concentration is presented as a dose
Do not convert 200 ng/mL in vitro into a human amount.
Oral and vial guidance conflict
The formulations and routes are not interchangeable.
A scheduled amount is missed
No validated missed-amount procedure exists.
Cartalax Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Cartalax | AED tripeptide | Cell-culture/preclinical evidence | Not approved |
| Cardiogen | AEDR tetrapeptide | Limited preclinical evidence | Not approved |
| BPC-157 | Synthetic pentadecapeptide | Primarily animal evidence | Not approved |
Cartalax Frequently Asked Questions
What is Cartalax?
The synthetic tripeptide Ala-Glu-Asp, also called AED.
Is it FDA approved?
No.
Are there human trials?
No controlled human Cartalax trial was identified.
What is its half-life?
Not established.
Is subcutaneous use validated?
No; it is community reported.
Can 200 ng/mL cell research define a human dose?
No.
Are joint benefits proven in people?
No.
Is the 12-week schedule validated?
No.
Is long-term safety known?
No.
What does the calculator do?
It performs concentration and volume arithmetic only.
Sources and Research
Coverage source
1. Cartalax protocol coverage source
Coverage source for community schedules; not primary clinical evidence.
Open direct sourceLaboratory research
2. Peptide regulation of chondrogenic stem-cell differentiation
Human stem-cell laboratory research using AED.
Open direct sourceLaboratory research
3. Effects of KE and AED peptides on aging human skin fibroblasts
In-vitro human fibroblast study; not a clinical trial.
Open direct sourcePreclinical review
4. Peptide regulation of gene expression: a systematic review
Review of short-peptide preclinical research.
Open direct sourceMissing information flagged for review
- Controlled human evidence: Not established
- Human dose and route: Not established
- Human and animal pharmacokinetics: Not established
- Validated cycle and rest period: Not established
- Compound-specific stability: Not established
- Human safety and interactions: Not established
- Independent replication: Not established